ENSC
Ensysce Biosciences, Inc.Company Information
- Company Name
- Ensysce Biosciences, Inc.
- CIK
- CIK0001716947
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ENSC: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ENSC
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-07
- Last sale
- —
- Shares purchased (TTM)
- 400,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 752,072
- Shares outstanding
- 13,035,632
- Ownership
- 5.77%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 30.66%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 1 | 1 | 4 | 2 | 2 | 3 | 4 | 4 | 1 | 3 | 1 | 1 | ||||||
| Unbilled Receivables Current | 0 | - | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense Current | - | - | - | - | - | - | - | - | - | - | - | 1 | ||||||
| Prepaid Expense And Other Assets Current | 2 | 1 | 3 | 1 | 2 | 1 | 2 | 3 | 1 | 1 | 1 | - | ||||||
| Assets Current | 3 | 2 | 7 | 3 | 5 | 4 | 5 | 9 | 2 | 5 | 2 | 3 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - | - | ||||||
| Other Assets Noncurrent | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 3 | 2 | 7 | 3 | 6 | 5 | 6 | 9 | 3 | 5 | 3 | 3 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 2 | 2 | 3 | 0 | 1 | 1 | 1 | 2 | 0 | 1 | 2 | 1 | ||||||
| Other Accrued Liabilities Current | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Notes Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | ||||||
| Liabilities Current | 4 | 3 | 5 | 2 | 3 | 2 | 2 | 3 | 1 | 2 | 3 | 2 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Other Liabilities Noncurrent | - | - | - | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Liabilities Noncurrent | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 4 | 3 | 5 | 2 | 3 | 2 | 2 | 3 | 1 | 2 | 3 | 2 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 145 | 143 | 143 | 138 | 137 | 135 | 133 | 133 | 128 | 128 | 121 | 120 | ||||||
| Retained Earnings Accumulated Deficit | -146 | -143 | -140 | -137 | -133 | -131 | -130 | -126 | -127 | -125 | -122 | -118 | ||||||
| Stockholders Equity | -1 | -1 | 3 | 1 | 3 | 3 | 4 | 7 | 1 | 3 | -1 | 1 | ||||||
| Minority Interest | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Liabilities And Stockholders Equity | 3 | 2 | 7 | 3 | 6 | 5 | 6 | 9 | 3 | 5 | 3 | 3 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Liquidation Preference Value | 1 | 2 | 4 | - | - | - | - | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 16 | 9 | 5 | 3 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 16 | 9 | 5 | 3 | 2 | 2 | 1 | 1 | 1 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEnsysce Biosciences, Inc. (ENSC) — SEC Financial Statements & Analysis
Ensysce Biosciences, Inc. (ENSC) is a pharmaceutical preparations company, incorporated in DE. Ensysce Biosciences, Inc. trades on Nasdaq as: ENSC. Ensysce Biosciences, Inc. (ENSC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Ensysce Biosciences, Inc. carries a market cap of $3.78M, a P/E ratio of -0.30x, a P/B ratio of -4.84x, a P/S ratio of 0.84x, an enterprise value of $3.30M, and an EV/EBITDA multiple of -0.26x. On profitability, it posts an operating margin of -281.32%, a net margin of -280.48%, a Return on Equity (ROE) of -968.33%, a Return on Assets (ROA) of -295.93%, and a Return on Invested Capital (ROIC) of -498.17%. Per share, it reports EPS of $-0.97, diluted EPS of $-0.97, free cash flow per share of $-0.69, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -39.29% year-over-year, net income growth of 91.80% year-over-year, and EPS growth of -67.60% year-over-year. On the balance sheet, it maintains a current ratio of 0.70x, a quick ratio of 0.27x, working capital of $-1.22M, a debt-to-equity ratio of -5.20x, a debt ratio of 1.38, an interest coverage ratio of -791.64x, free cash flow of $-8.98M (TTM), and net debt of $-479.86K. Figures sourced from SEC EDGAR.
- Market Cap
- $3.78M
- P/E TTM
- -0.30x
- EPS TTM
- $-0.97
- P/B TTM
- -4.84x
- ROE TTM
- -968.33%
- ROA TTM
- -295.93%
- Debt To Equity
- -5.20x
- Free Cash Flow TTM
- $-8.98M
- Net Revenue TTM Growth 1Y
- -39.29%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Ensysce Biosciences, Inc. in?
Ensysce Biosciences, Inc. (ENSC) operates in the Pharmaceutical Preparations industry.
What exchange does ENSC trade on?
Ensysce Biosciences, Inc. (ENSC) trades on the Nasdaq.
Where is Ensysce Biosciences, Inc. incorporated?
Ensysce Biosciences, Inc. is incorporated in DE.
When was Ensysce Biosciences, Inc. (ENSC)'s most recent SEC filing?
Ensysce Biosciences, Inc. (ENSC)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is ENSC's market cap?
Ensysce Biosciences, Inc. (ENSC) has a market capitalization of $3.78M as of 2026-06-30.
What is ENSC's EPS (earnings per share)?
Ensysce Biosciences, Inc. (ENSC)'s trailing twelve month EPS is $-0.97 as of 2026-06-30.
What is ENSC's ROE (return on equity)?
Ensysce Biosciences, Inc. (ENSC)'s trailing twelve month Return on Equity (ROE) is -968.33% as of 2026-06-30.
What is ENSC's ROA (return on assets)?
Ensysce Biosciences, Inc. (ENSC)'s trailing twelve month Return on Assets (ROA) is -295.93% as of 2026-06-30.
What is ENSC's ROIC (return on invested capital)?
Ensysce Biosciences, Inc. (ENSC)'s trailing twelve month Return on Invested Capital (ROIC) is -498.17% as of 2025-06-30.
What is ENSC's EV/EBITDA?
Ensysce Biosciences, Inc. (ENSC)'s trailing twelve month EV/EBITDA is -0.26x as of 2026-06-30.